**Roche to Invest $50 Billion in Expanding U.S. Manufacturing Footprint**
Roche, the Switzerland-based pharmaceutical giant, has announced plans to invest $50 billion in the United States over the next five years. This significant investment will support the expansion and modernization of the company’s U.S. operations, including manufacturing and distribution facilities across the country.
The initiative includes major expansions and upgrades to existing facilities in Kentucky, Indiana, New Jersey, Oregon, and California. It also features the construction of key new sites: a gene therapy manufacturing facility in Pennsylvania, a continuous glucose monitoring production facility in Indiana, and a new R&D center in Massachusetts. Additionally, Roche has plans to develop a 900,000-square-foot manufacturing center focused on next-generation weight loss medications, with the location yet to be disclosed.
Thomas Schinecker, CEO of the Roche Group, emphasized the global implications of the investment, stating, “Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the U.S. and around the world.”
Upon completion, Roche expects to reverse the current balance of trade in its pharmaceuticals, exporting more medicines from the U.S. than it imports.
*Pictured: Roche’s Genentech campus in San Francisco.*
